Commentary: Evaluating ocular surface disease in glaucoma
- PMID: 35502040
- PMCID: PMC9332935
- DOI: 10.4103/ijo.IJO_452_22
Commentary: Evaluating ocular surface disease in glaucoma
Conflict of interest statement
None
Comment on
-
Changes in ocular surface after withdrawal of anti-glaucoma medications following non-penetrating deep sclerectomy.Indian J Ophthalmol. 2022 May;70(5):1626-1633. doi: 10.4103/ijo.IJO_2654_21. Indian J Ophthalmol. 2022. PMID: 35502039 Free PMC article.
References
-
- Leung EW, Medeiros FA, Weinreb RN. Prevalenceof ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5. - PubMed
-
- Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOSDEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–74. - PubMed
-
- Agnifili L, Brescia L, Scatena B, Oddone F, Figus M, Perna F, et al. Tearmeniscus imaging by anterior segment-optical coherence tomography in medically controlled glaucoma. J Glaucoma. 2020;29:374–80. - PubMed
-
- Carnevale C, Riva I, Roberti G, Michelessi M, Tanga L, Verticchio Vercellin AC, et al. Confocalmicroscopy and anterior segmentoptical coherence tomography imaging of the ocular surface and blebmorphology in medically and surgically treated glaucoma patients: A review. Pharmaceuticals (Basel) 2021;14:581. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
